Trial NCT05622058

View at ClinicalTrials.gov 
Org. Study IDs: ALRN-6924-1-05
Secondary IDs: 2022-000158-27

Last trial update was posted on 2023-02-27

MeSH Interventions

Cyclophosphamide Docetaxel Doxorubicin

MeSH Conditions

Breast Neoplasms

Other Conditions

Prevention of Chemotherapy-induced Myelosuppression

Stopping Reasons

The study has been terminated early given that the first four patients enrolled have experienced Grade 4 neutropenia and alopecia after cycle 1 and as such failed to meet the primary endpoint and the main secondary endpoint.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID